title: Sodium-glucose cotransporter-2 inhibitors: Expanding oral treatment options for type 2 diabetes mellitus.
abstract: The number of patients with type 2 diabetes mellitus (T2DM) continues to increase in the United States. Glycemic control among patients with diabetes is important to prevent future complications, including microvascular and macrovascular disease. A novel class of medications, sodium-glucose cotransporter-2 inhibitors, presents an additional oral treatment option for patients with T2DM.
authors.affiliation: Emily Ashjian is a clinical pharmacist in ambulatory care at the University of Michigan Health System, Ann Arbor, Mich. Jeffrey Tingen is a clinical pharmacist in ambulatory care at the Department of Pharmacy Services at the University of Virginia Health System, Charlottesville, Va.
authors.forename: Emily
authors.initials: E
authors.lastname: Ashjian
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Tingen
mesh_terms: D000284:Administration, Oral; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D000077203:Sodium-Glucose Transporter 2 Inhibitors / Q000008:administration & dosage*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000077203:Sodium-Glucose Transporter 2 Inhibitors